Use of inspiratory profiles from patients with chronic obstructive pulmonary disease (COPD) to investigate drug delivery uniformity and aerodynamic dose emission of indacaterol from a capsule based dry powder inhaler
Most patients using dry powder inhalers (DPIs) are unable to achieve the inhalation parameters recommended for pharmacopoeial in-vitro dose emission testing. The dose emission characteristics of indacaterol Breezhaler (IB) have been measured using COPD patients' inhalation profiles (IPs) when u...
Gespeichert in:
| Veröffentlicht in: | European journal of pharmaceutical sciences 2019-06, Vol.134, p.138-144 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 144 |
|---|---|
| container_issue | |
| container_start_page | 138 |
| container_title | European journal of pharmaceutical sciences |
| container_volume | 134 |
| creator | Abadelah, Mohamad Chrystyn, Henry Larhrib, Hassan |
| description | Most patients using dry powder inhalers (DPIs) are unable to achieve the inhalation parameters recommended for pharmacopoeial in-vitro dose emission testing. The dose emission characteristics of indacaterol Breezhaler (IB) have been measured using COPD patients' inhalation profiles (IPs) when using IB and replayed in-vitro using a breath simulator attached to an Andersen Cascade Impactor. The peak inhalation flow (PIF) of the profiles ranged from 28.3 to 87.8 L/min and inhaled volumes (Vin) from 0.7 to 3 L. The indacaterol total emitted doses (TED), fine particle dose (FPD) and mass median aerodynamic diameter (MMAD) were measured. TED varied between 61% to 83% of the 150 μg nominal dose, the FPD was found to vary between 19% and 30% and the MMAD from 3.7 μm to 2.3 μm with the increase of the profiles' PIF and Vin. The mean (SD) values were 113.4(8.9) μg, 39.7(5.0) μg and 2.7(0.5) μm, respectively. The quantity and the quality of the emitted dose from the indacaterol Breezhaler® are dependent on the capability of a patient generating an optimal inhalation profile. Therefore, when using the IB patients should be encouraged to inhale as fast as they can from the start of their inhalation and for as long as possible.
[Display omitted] |
| doi_str_mv | 10.1016/j.ejps.2019.04.018 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2212726593</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0928098719301629</els_id><sourcerecordid>2212726593</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-a14e196ef45abc25f99ae4df1d5b85d23f948ad51d17069c365ddd1044109f243</originalsourceid><addsrcrecordid>eNp9kU9vEzEQxVcIREPhC3BAPpZDwtj71xIXlEJBqlQO9Gw59rhxtLtebG-qfFM-DhNt6ZHTXN77zZt5RfGew4YDbz4dNniY0kYAlxuoNsC7F8WKd61cQyvgZbECKbo1yK69KN6kdACApmvhdXFRcoC6EeWq-HOfkAXH_JgmH3UO8cSmGJzvMTEXw8AmnT2OObFHn_fM7GMYvWFhl3KcTfZHZNPcD2HU5LQ-oSbg1fbu5_VHlgNxj5iyf9AZmY3zA7PYk4e08-hdiIPPJ6ZHyzTGYE-jHghuAzFw8Cn5MC7prDaEiKFfQmlm9JTmHtmO9llCU-zwaDGSdq97jG-LV073Cd89zcvi_tvXX9vv69u7mx_bL7drUwHkteYVctmgq2q9M6J2UmqsrOO23nW1FaWTVadtzS1voZGmbGprLYeq4iCdqMrL4mrh0td-z3SrotwG-16PGOakhOCiFU0tS5KKRWpiSCmiU1P0A_1NcVDnRtVBnRtV50YVVIoaJdOHJ_68G9A-W_5VSILPiwDpyqPHqJKhwgxaH9FkZYP_H_8v8f24rw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2212726593</pqid></control><display><type>article</type><title>Use of inspiratory profiles from patients with chronic obstructive pulmonary disease (COPD) to investigate drug delivery uniformity and aerodynamic dose emission of indacaterol from a capsule based dry powder inhaler</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Abadelah, Mohamad ; Chrystyn, Henry ; Larhrib, Hassan</creator><creatorcontrib>Abadelah, Mohamad ; Chrystyn, Henry ; Larhrib, Hassan</creatorcontrib><description>Most patients using dry powder inhalers (DPIs) are unable to achieve the inhalation parameters recommended for pharmacopoeial in-vitro dose emission testing. The dose emission characteristics of indacaterol Breezhaler (IB) have been measured using COPD patients' inhalation profiles (IPs) when using IB and replayed in-vitro using a breath simulator attached to an Andersen Cascade Impactor. The peak inhalation flow (PIF) of the profiles ranged from 28.3 to 87.8 L/min and inhaled volumes (Vin) from 0.7 to 3 L. The indacaterol total emitted doses (TED), fine particle dose (FPD) and mass median aerodynamic diameter (MMAD) were measured. TED varied between 61% to 83% of the 150 μg nominal dose, the FPD was found to vary between 19% and 30% and the MMAD from 3.7 μm to 2.3 μm with the increase of the profiles' PIF and Vin. The mean (SD) values were 113.4(8.9) μg, 39.7(5.0) μg and 2.7(0.5) μm, respectively. The quantity and the quality of the emitted dose from the indacaterol Breezhaler® are dependent on the capability of a patient generating an optimal inhalation profile. Therefore, when using the IB patients should be encouraged to inhale as fast as they can from the start of their inhalation and for as long as possible.
[Display omitted]</description><identifier>ISSN: 0928-0987</identifier><identifier>EISSN: 1879-0720</identifier><identifier>DOI: 10.1016/j.ejps.2019.04.018</identifier><identifier>PMID: 31005623</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Acceleration rate (ACIM) ; Administration, Inhalation ; Aged ; Andersen Cascade Impactor (ACI) ; Breath simulator (BRS) ; Drug Delivery Systems ; Dry Powder Inhalers - instrumentation ; Dry Powder Inhalers - methods ; Female ; Humans ; Indacaterol Breezhaler® (IB) ; Indans - administration & dosage ; Inhalation volume (Vin) ; Inspiratory Capacity ; Lung ; Male ; Middle Aged ; Outcome Assessment, Health Care ; Peak inhalation flow (PIF) ; Powders ; Pulmonary Disease, Chronic Obstructive - drug therapy ; Quinolones - administration & dosage ; Respiratory Therapy - instrumentation ; Respiratory Therapy - methods</subject><ispartof>European journal of pharmaceutical sciences, 2019-06, Vol.134, p.138-144</ispartof><rights>2019</rights><rights>Copyright © 2019. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-a14e196ef45abc25f99ae4df1d5b85d23f948ad51d17069c365ddd1044109f243</citedby><cites>FETCH-LOGICAL-c400t-a14e196ef45abc25f99ae4df1d5b85d23f948ad51d17069c365ddd1044109f243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejps.2019.04.018$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27928,27929,45999</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31005623$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abadelah, Mohamad</creatorcontrib><creatorcontrib>Chrystyn, Henry</creatorcontrib><creatorcontrib>Larhrib, Hassan</creatorcontrib><title>Use of inspiratory profiles from patients with chronic obstructive pulmonary disease (COPD) to investigate drug delivery uniformity and aerodynamic dose emission of indacaterol from a capsule based dry powder inhaler</title><title>European journal of pharmaceutical sciences</title><addtitle>Eur J Pharm Sci</addtitle><description>Most patients using dry powder inhalers (DPIs) are unable to achieve the inhalation parameters recommended for pharmacopoeial in-vitro dose emission testing. The dose emission characteristics of indacaterol Breezhaler (IB) have been measured using COPD patients' inhalation profiles (IPs) when using IB and replayed in-vitro using a breath simulator attached to an Andersen Cascade Impactor. The peak inhalation flow (PIF) of the profiles ranged from 28.3 to 87.8 L/min and inhaled volumes (Vin) from 0.7 to 3 L. The indacaterol total emitted doses (TED), fine particle dose (FPD) and mass median aerodynamic diameter (MMAD) were measured. TED varied between 61% to 83% of the 150 μg nominal dose, the FPD was found to vary between 19% and 30% and the MMAD from 3.7 μm to 2.3 μm with the increase of the profiles' PIF and Vin. The mean (SD) values were 113.4(8.9) μg, 39.7(5.0) μg and 2.7(0.5) μm, respectively. The quantity and the quality of the emitted dose from the indacaterol Breezhaler® are dependent on the capability of a patient generating an optimal inhalation profile. Therefore, when using the IB patients should be encouraged to inhale as fast as they can from the start of their inhalation and for as long as possible.
[Display omitted]</description><subject>Acceleration rate (ACIM)</subject><subject>Administration, Inhalation</subject><subject>Aged</subject><subject>Andersen Cascade Impactor (ACI)</subject><subject>Breath simulator (BRS)</subject><subject>Drug Delivery Systems</subject><subject>Dry Powder Inhalers - instrumentation</subject><subject>Dry Powder Inhalers - methods</subject><subject>Female</subject><subject>Humans</subject><subject>Indacaterol Breezhaler® (IB)</subject><subject>Indans - administration & dosage</subject><subject>Inhalation volume (Vin)</subject><subject>Inspiratory Capacity</subject><subject>Lung</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Outcome Assessment, Health Care</subject><subject>Peak inhalation flow (PIF)</subject><subject>Powders</subject><subject>Pulmonary Disease, Chronic Obstructive - drug therapy</subject><subject>Quinolones - administration & dosage</subject><subject>Respiratory Therapy - instrumentation</subject><subject>Respiratory Therapy - methods</subject><issn>0928-0987</issn><issn>1879-0720</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9vEzEQxVcIREPhC3BAPpZDwtj71xIXlEJBqlQO9Gw59rhxtLtebG-qfFM-DhNt6ZHTXN77zZt5RfGew4YDbz4dNniY0kYAlxuoNsC7F8WKd61cQyvgZbECKbo1yK69KN6kdACApmvhdXFRcoC6EeWq-HOfkAXH_JgmH3UO8cSmGJzvMTEXw8AmnT2OObFHn_fM7GMYvWFhl3KcTfZHZNPcD2HU5LQ-oSbg1fbu5_VHlgNxj5iyf9AZmY3zA7PYk4e08-hdiIPPJ6ZHyzTGYE-jHghuAzFw8Cn5MC7prDaEiKFfQmlm9JTmHtmO9llCU-zwaDGSdq97jG-LV073Cd89zcvi_tvXX9vv69u7mx_bL7drUwHkteYVctmgq2q9M6J2UmqsrOO23nW1FaWTVadtzS1voZGmbGprLYeq4iCdqMrL4mrh0td-z3SrotwG-16PGOakhOCiFU0tS5KKRWpiSCmiU1P0A_1NcVDnRtVBnRtV50YVVIoaJdOHJ_68G9A-W_5VSILPiwDpyqPHqJKhwgxaH9FkZYP_H_8v8f24rw</recordid><startdate>20190615</startdate><enddate>20190615</enddate><creator>Abadelah, Mohamad</creator><creator>Chrystyn, Henry</creator><creator>Larhrib, Hassan</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20190615</creationdate><title>Use of inspiratory profiles from patients with chronic obstructive pulmonary disease (COPD) to investigate drug delivery uniformity and aerodynamic dose emission of indacaterol from a capsule based dry powder inhaler</title><author>Abadelah, Mohamad ; Chrystyn, Henry ; Larhrib, Hassan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-a14e196ef45abc25f99ae4df1d5b85d23f948ad51d17069c365ddd1044109f243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acceleration rate (ACIM)</topic><topic>Administration, Inhalation</topic><topic>Aged</topic><topic>Andersen Cascade Impactor (ACI)</topic><topic>Breath simulator (BRS)</topic><topic>Drug Delivery Systems</topic><topic>Dry Powder Inhalers - instrumentation</topic><topic>Dry Powder Inhalers - methods</topic><topic>Female</topic><topic>Humans</topic><topic>Indacaterol Breezhaler® (IB)</topic><topic>Indans - administration & dosage</topic><topic>Inhalation volume (Vin)</topic><topic>Inspiratory Capacity</topic><topic>Lung</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Outcome Assessment, Health Care</topic><topic>Peak inhalation flow (PIF)</topic><topic>Powders</topic><topic>Pulmonary Disease, Chronic Obstructive - drug therapy</topic><topic>Quinolones - administration & dosage</topic><topic>Respiratory Therapy - instrumentation</topic><topic>Respiratory Therapy - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abadelah, Mohamad</creatorcontrib><creatorcontrib>Chrystyn, Henry</creatorcontrib><creatorcontrib>Larhrib, Hassan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abadelah, Mohamad</au><au>Chrystyn, Henry</au><au>Larhrib, Hassan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of inspiratory profiles from patients with chronic obstructive pulmonary disease (COPD) to investigate drug delivery uniformity and aerodynamic dose emission of indacaterol from a capsule based dry powder inhaler</atitle><jtitle>European journal of pharmaceutical sciences</jtitle><addtitle>Eur J Pharm Sci</addtitle><date>2019-06-15</date><risdate>2019</risdate><volume>134</volume><spage>138</spage><epage>144</epage><pages>138-144</pages><issn>0928-0987</issn><eissn>1879-0720</eissn><abstract>Most patients using dry powder inhalers (DPIs) are unable to achieve the inhalation parameters recommended for pharmacopoeial in-vitro dose emission testing. The dose emission characteristics of indacaterol Breezhaler (IB) have been measured using COPD patients' inhalation profiles (IPs) when using IB and replayed in-vitro using a breath simulator attached to an Andersen Cascade Impactor. The peak inhalation flow (PIF) of the profiles ranged from 28.3 to 87.8 L/min and inhaled volumes (Vin) from 0.7 to 3 L. The indacaterol total emitted doses (TED), fine particle dose (FPD) and mass median aerodynamic diameter (MMAD) were measured. TED varied between 61% to 83% of the 150 μg nominal dose, the FPD was found to vary between 19% and 30% and the MMAD from 3.7 μm to 2.3 μm with the increase of the profiles' PIF and Vin. The mean (SD) values were 113.4(8.9) μg, 39.7(5.0) μg and 2.7(0.5) μm, respectively. The quantity and the quality of the emitted dose from the indacaterol Breezhaler® are dependent on the capability of a patient generating an optimal inhalation profile. Therefore, when using the IB patients should be encouraged to inhale as fast as they can from the start of their inhalation and for as long as possible.
[Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>31005623</pmid><doi>10.1016/j.ejps.2019.04.018</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0928-0987 |
| ispartof | European journal of pharmaceutical sciences, 2019-06, Vol.134, p.138-144 |
| issn | 0928-0987 1879-0720 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2212726593 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Acceleration rate (ACIM) Administration, Inhalation Aged Andersen Cascade Impactor (ACI) Breath simulator (BRS) Drug Delivery Systems Dry Powder Inhalers - instrumentation Dry Powder Inhalers - methods Female Humans Indacaterol Breezhaler® (IB) Indans - administration & dosage Inhalation volume (Vin) Inspiratory Capacity Lung Male Middle Aged Outcome Assessment, Health Care Peak inhalation flow (PIF) Powders Pulmonary Disease, Chronic Obstructive - drug therapy Quinolones - administration & dosage Respiratory Therapy - instrumentation Respiratory Therapy - methods |
| title | Use of inspiratory profiles from patients with chronic obstructive pulmonary disease (COPD) to investigate drug delivery uniformity and aerodynamic dose emission of indacaterol from a capsule based dry powder inhaler |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T11%3A44%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20inspiratory%20profiles%20from%20patients%20with%20chronic%20obstructive%20pulmonary%20disease%20(COPD)%20to%20investigate%20drug%20delivery%20uniformity%20and%20aerodynamic%20dose%20emission%20of%20indacaterol%20from%20a%20capsule%20based%20dry%20powder%20inhaler&rft.jtitle=European%20journal%20of%20pharmaceutical%20sciences&rft.au=Abadelah,%20Mohamad&rft.date=2019-06-15&rft.volume=134&rft.spage=138&rft.epage=144&rft.pages=138-144&rft.issn=0928-0987&rft.eissn=1879-0720&rft_id=info:doi/10.1016/j.ejps.2019.04.018&rft_dat=%3Cproquest_cross%3E2212726593%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2212726593&rft_id=info:pmid/31005623&rft_els_id=S0928098719301629&rfr_iscdi=true |